By silencing both PD-L1/PD-L2 immune checkpoints and activating antigen-specific pathways, this dual delivery approach demonstrated stimulatory potential in enhancing ex vivo responses in translated cancer patients [189]. This evidence concerns the gene CD274 and cancer.